

# COMPLETE PROBIOTICS PORTFOLIO: READY-TO-MARKET SOLUTIONS

Microbiome for Human Health  
Pioneering Innovative Probiotic Solutions

 CELL BIOTECH

# PROBIOTICS SPECIALISTS FOR OEM / ODM

## PROBIOTICS ONE STOP SOLUTION

- Probiotics Specialist with 30-Year Experience
- From Lab to Shelf and Marketing Support
- **Customized OEM Services**

## WORLDWIDE PATENTED COATING TECHNOLOGY

- Patent in Europe, USA, South Korea, Japan and China
- **100 Times Higher Survival Rate**

## SAFETY EVALUATION FROM ALL ANGLES

- **GRAS Noticed by U.S. FDA**
- Human Origin Strains
- Strain Deposit
- *In-vitro, In-vivo*, Clinical Trials
- Whole Genome Sequencing
- 16S rRNA Sequence Analysis
- Antibiotic Resistance Test
- Toxicity Assessment



## IN-HOUSE FERMENTATION FOR HIGHEST QUALITY

- Fully Automated Control System
- **Fermentation Facilities for The Highest Quality**



## GENETIC-BASED FORMULATION TECHNOLOGY

- **Genome Identification for Targeted Functionality**
- R&D Leads the Full Process of Formulation
- Formulation Considering Different Growth Rates of the 3 Genera
- Formulation Tailored for Microbiome Diversity by Age



## PROBIOTICS-CENTRIC MANUFACTURING FACILITIES

- Optimized Facilities for Maximum Probiotics Viability
- **Internalized Process from Start to Finish**
- Made-to-order Solutions



## GLOBAL QUALITY CONTROL STANDARDS

- Independent Line Audit System
- Global Certifications and EMS(Environmental Management Systems)
- **MUI HALAL, KOSHER, GMP, HACCP, ISO9001, ISO 14001, GRAS**



## MARKETING PARTNERSHIPS

- A Wide Range of Marketing Service for Your Growth
- **Seminars, Academic Conferences, KOL Invitation**

# COMPLETE PROBIOTICS SOLUTIONS

## FOR DAILY WELL BEING OF ALL AGES

Daily concepts are for everyone and everyday use to support and maintain a healthy internal balance, a strong immune defense and a well functioning gut.


Category	Name	Concept
Baby	<b>New Born Baby™</b>	Baby Growth (HMOs)
	<b>Happy Baby™</b>	Toddler Gut health
	<b>Milk Again™</b>	Lactose Intolerance
Kids	<b>Healthy Kids™</b>	Kids Gut Health
Adult	<b>Daily Vitality™</b>	Adult Gut Health
Senior	<b>65+Vitality™</b>	Complete 65+ Care
Women	<b>Mom™</b>	Prenatal and Postnatal Care
	<b>Women Balance™</b>	Vaginal Microbiome
Family	<b>Bio Guard™</b>	Family Care
	<b>Quercetin™</b>	Family Immune Health

## LAB2PRO®

### BRAND ELEMENTS FOR B2B CUSTOMERS



The diamond, strong and durable, illustrates the power that our technology system offers to protect valuable probiotic strains in the core. All Cell Biotech probiotics including single strain, premix powders and finished concepts, are branded LAB2PRO® to guarantee the uniqueness and high quality delivered.



## FOR TARGETED HEALTH BENEFITS

Our special probiotics formulation are targeted for those situations where extra help is needed to recover and restore the specific symptoms and disease.

Category	Name	Concept
Gut Health	<b>Premium Care™</b>	IBS, IBD, Constipation
	<b>Calm Gut™</b>	IBS
	<b>Travel™</b>	Traveler's Diarrhea
Women Health	<b>Meno-Pro™</b>	Anti-Menopause
Skin Health	<b>Derma Plus™</b>	Atopic Dermatitis
Liver Health	<b>Fresh Morning™</b>	Hang Over
Mental Health	<b>Good Mood™</b>	Depression
Muscle Health	<b>Protein Plus™</b>	Protein Absorption
Oral Health	<b>Dental™</b>	Periodontitis, Cavity
Pet Health	<b>Slim Dog™</b>	Dog Obesity

# BABY HEALTH

LAB2PRO® NEWBORN

0 - 12 MONTHS



## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for newborns
- Clinically proven to be safe for infants aged 0-12 months with no adverse effects<sup>①</sup>
- 4 *Bifidobacterium* strains proven for human milk oligosaccharide (HMO) utilization<sup>②</sup> and vitamin B biosynthesis<sup>③</sup>
- Full genome sequenced<sup>④</sup> for 4 *bifidobacterium* strains
- 4 patented *bifidobacterium* strains for promotion of growth<sup>⑤</sup>
- Especially for babies born by caesarean section or who are not breastfed
- Easy-to-take liquid drops for babies

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-BT1	●	Growth
CBT-BR3	●	Growth
CBT-BG7	●	Growth
CBT-BF3	●	Growth
<b>CFU</b>	500 Million / 6 Drops	
<b>OTHER INGREDIENT</b>	Vitamin D3, MCT-Oil	
<b>DOSAGE FORM</b>	Oil Drop (Reducer, Dropper)	
<b>DIRECTION</b>	Gently dispense drops into milk or directly into your baby's mouth	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Infant fecal microbiota / No adverse effects <sup>①</sup>	ALL
<i>in-vitro</i>	HMOs utilization <sup>②</sup> / Vitamin B biosynthesis <sup>③</sup>	ALL
Genomic Research	Full genome sequencing <sup>④</sup>	ALL
Patent	Promotion of growth <sup>⑤</sup>	ALL

# BABY HEALTH

LAB2PRO® HAPPY BABY

6 - 24 MONTHS



## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for babies
- Clinically proven to shorten the duration of diarrhea caused by rotavirus<sup>①</sup> in pediatric patients aged 3 months to 7 years
- In the probiotics group, the VP7 gene level of rotavirus in fecal samples and small intestinal epithelial cells was lower<sup>②</sup>
- Protecting activities of CBT-SL4 against *H. pylori* infection<sup>③</sup>
- CBT-LP3, CBT-LA1 can be used as a potent immunomodulator in IBD treatment<sup>④⑤</sup>
- 1 *Bifidobacterium* strain proven for human milk oligosaccharide (HMO) utilization<sup>⑥</sup> and vitamin B biosynthesis<sup>⑦</sup>
- 1 patented *bifidobacterium* strain for promotion of growth<sup>⑧</sup>
- Flavorless, fine powder mixes effortlessly with breast milk or formula

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LP3	●	
CBT-LA1	●	
CBT-LR5	●	
CBT-BG7	●	Growth
CBT-BL3	●	
CBT-SL4		
<b>CFU</b>	500 Million / 1 Stick	
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides)	
<b>DOSAGE FORM</b>	Stick Powder	
<b>DIRECTION</b>	Mix with milk or water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Rotavirus <sup>①</sup>	ALL
<i>in-vitro</i> & <i>in-vivo</i>	Anti-rotaviral activities <sup>②</sup>	ALL
<i>in-vivo</i>	Prevention of <i>H. pylori</i> <sup>③</sup>	CBT-SL4
<i>in-vivo</i>	IBD, Inflammatory bowel disease <sup>④</sup>	CBT-LP3
<i>in-vitro</i> & <i>in-vivo</i>	IBD, Intestinal Inflammation <sup>⑤</sup>	CBT-LA1, CBT-SL4
<i>in-vitro</i>	HMOs utilization / Vitamin B biosynthesis <sup>⑦</sup>	CBT-BG7
Patent	Promotion of growth <sup>⑧</sup>	CBT-BG7

# BABY HEALTH

LAB2PRO® MILK AGAIN

6 - 24 MONTHS



## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for babies
- Clinically proven to shorten the duration of acute diarrhea<sup>①</sup>
- Clinically proven to relieve lactose intolerance symptoms in children<sup>②</sup>
- 1 *Bifidobacterium* strain proven for HMO utilization<sup>③</sup> and vitamin B biosynthesis<sup>④</sup>
- 1 patented *bifidobacterium* strain for promotion of growth<sup>⑤</sup>
- Flavorless, fine powder mixes effortlessly with breast milk or formula
- Especially for babies who have difficulty digesting lactose

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	
CBT-BG7	●	Growth
CBT-ST3	●	
<b>CFU</b>	1 Billion / 1 Stick	
<b>OTHER INGREDIENT</b>	Milk Mineral Concentrate, FOS, Zinc, Vitamin C, B1, B2, B6	
<b>DOSAGE FORM</b>	Stick Powder	
<b>DIRECTION</b>	Mix with milk or water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Acute Diarrhea <sup>①</sup>	ALL
Clinical Trial	Relieve lactose intolerance symptoms <sup>②</sup>	ALL
<i>in-vitro</i>	HMOs utilization <sup>③</sup> / Vitamin B biosynthesis <sup>④</sup>	CBT-BG7
Patent	Promotion of growth <sup>⑤</sup>	CBT-BG7

# KIDS HEALTH

LAB2PRO® HEALTHY KIDS

24 MONTHS - 13 YEARS



## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for kids
- Clinically proven to shorten the duration of diarrhea caused by rotavirus<sup>①</sup> in pediatric patients aged 3 months to 7 years
- Protecting activities of CBT-SL4 against *H. pylori* infection<sup>②</sup>
- CBT-LP3, CBT-LA1 can be used as a potent immunomodulator in IBD treatment<sup>③④</sup>
- 1 *Bifidobacterium* strain proven for human milk oligosaccharide (HMO) utilization<sup>⑤</sup> and vitamin B biosynthesis<sup>⑥</sup>
- 1 patented *bifidobacterium* strain for promotion of growth<sup>⑦</sup>
- Yummy and easy-to-chew tablets that kids will love

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LP3	●	Obesity
CBT-LA1	●	Obesity
CBT-LR5	●	Obesity
CBT-BG7	●	Growth
CBT-BL3	●	Obesity
CBT-SL4		Obesity
<b>CFU</b>	2 Billion / 1 Tablet	
<b>OTHER INGREDIENT</b>	FOS, Vitamin D, Zinc, Calcium	
<b>DOSAGE FORM</b>	Chewable Tablet	
<b>DIRECTION</b>	Chew thoroughly before swallowing	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Rotavirus <sup>①</sup>	ALL
<i>in-vivo</i>	Prevention of <i>H. pylori</i> <sup>②</sup>	CBT-SL4
<i>in-vivo</i>	IBD, Inflammatory bowel disease <sup>③</sup>	CBT-LP3
<i>in-vitro</i> & <i>in-vivo</i>	IBD, Intestinal Inflammation <sup>④</sup>	CBT-LA1, CBT-SL4
<i>in-vitro</i>	HMOs utilization / Vitamin B biosynthesis <sup>⑥</sup>	ALL
Patent	Promotion of growth <sup>⑦</sup>	CBT-BG7
Patent	Prevention or treatment of obesity <sup>⑧</sup>	CBT-LR5, CBT-LP3, CBT-LA1, CBT-BL3, CBT-SL4

# ADULT HEALTH

LAB2PRO® DAILY VITALITY

+ 13 YEARS



# SENIOR HEALTH

LAB2PRO® +65 VITALITY

+ 65 YEARS



# PRENATAL AND POSTNATAL HEALTH

LAB2PRO® MOM

PREGNANT



# VAGINAL HEALTH

LAB2PRO® WOMEN BALANCE

WOMEN



## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for adults
- Clinically proven to have an effect on the global relief of IBS symptoms<sup>①</sup>
- Clinically proven to attenuate diarrhea-related symptoms in IBS patients<sup>②</sup>
- Clinically proven to have a significant improvement in constipation symptoms<sup>③</sup>
- Effective in IBD healing by regulating interleukin-6<sup>④</sup>
- Antibacterial effect<sup>⑤</sup> against *E. coli* and *S. typhimurium*
- Patented composition for preventing or treating IBS<sup>⑥</sup>
- Easy to swallow vegetable capsule for adult

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	IBS
CBT-LR5	●	IBS
CBT-BL3	●	IBS
CBT-BG7	●	IBS
CBT-BF3	●	IBS
CBT-ST3	●	IBS
<b>CFU</b>	7 Billion / 1 Capsule	
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides), Vitamin C	
<b>DOSAGE FORM</b>	Vegetable Capsule	
<b>DIRECTION</b>	Take 1 capsule directly with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Irritable bowel syndrome (IBS) <sup>①</sup>	ALL
Clinical Trial	Irritable bowel syndrome (IBS) <sup>②</sup>	ALL
Clinical Trial	Constipation <sup>③</sup>	ALL
<i>in-vivo</i>	Inflammatory bowel disease (IBD) <sup>④</sup>	ALL
<i>in-vitro</i>	Antibacterial effect <sup>⑤</sup>	CBT-LA1, CBT-BF3, CBT-ST3
Patent	Irritable bowel syndrome (IBS) <sup>⑥</sup>	ALL
Patent	Prevention or treatment of obesity <sup>⑦</sup>	CBT-LA1, CBT-LR5, CBT-BL3

## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for adults
- Effective in alleviation of intestinal complications caused by medications<sup>①</sup> for rheumatoid arthritis (leflunomide) and hypertension (amlodipine)
- Effective in preventing chronic small intestinal injury induced by NSAID medication<sup>②</sup>
- CBT-LC5 significantly reduced the severity and clinical symptoms of arthritis<sup>③</sup>
- Patented heat-killed bacteria ProLac-T<sup>™</sup> removes lipopolysaccharides (LPS)<sup>④</sup> from the intestine, a common trigger of intestinal inflammation.
- Aquamin-F is a natural mineral source produced from seaweed, a highly bioactive source of minerals rich in calcium
- Especially for those who take chronic medication
- Easy-to-chew tablets for seniors with swallowing difficulties

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	IBS
CBT-LR5	●	IBS
CBT-BL3	●	IBS
CBT-BG7	●	IBS
CBT-BF3	●	IBS
CBT-ST3	●	IBS
CBT-LC5	●	
<b>ProLac-T<sup>™</sup></b>		Antibacterial Effect
<b>CFU</b>	12 Billion / 2 Tablets	
<b>OTHER INGREDIENT</b>	FOS, Xylitol, Vitamin D, Vitamin B12, Zinc, Seaweed Calcium	
<b>DOSAGE FORM</b>	Chewable Tablet	
<b>DIRECTION</b>	Chew thoroughly before swallowing	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<i>in-vivo</i>	Gastrointestinal side effects <sup>①</sup> Leflunomide & amlodipine	ALL (without CBT-LC5)
<i>in-vivo</i>	Gastrointestinal side effects <sup>②</sup> NSAIDs, indomethacin	ALL (without CBT-LC5)
<i>in-vivo</i>	Rheumatoid arthritis <sup>③</sup>	CBT-LC5
<i>in-vitro</i> & <i>in-vivo</i>	Binding and removal of LPS <sup>④</sup>	PROLAC-T <sup>™</sup>
Patent	Irritable bowel syndrome (IBS) <sup>⑤</sup>	ALL (without CBT-LC5)
Patent	Manufacturing methods of antibacterial compounds <sup>⑥</sup>	PROLAC-T <sup>™</sup>

## KEY FEATURES

- To support gut health and maintain a beneficial gut flora during pregnancy and lactation
- Maternal vaginal *bifidobacteria*, baby's first bacteria, are very important or establishing intestinal *bifidobacteria* in infants
- Clinically proven to be safe for infants aged 0-12 months with no adverse effects<sup>①</sup>
- 4 *Bifidobacterium* strains proven for HMO utilization<sup>②</sup> and vitamin B biosynthesis<sup>③</sup>
- Full genome sequenced<sup>④</sup> for 4 *bifidobacterium* strains
- 4 patented *bifidobacterium* strains for promotion of growth<sup>⑤</sup>
- CBT-LGA1 carefully isolated from healthy mother's milk
- Especially for mom, her developing baby, and her infant
- Easy to swallow vegetable capsule for pregnant (No color, No fragrance, No GMO)

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LGA1		
CBT-LU4		
CBT-BT1	●	Growth
CBT-BR3	●	Growth
CBT-BG7	●	Growth
CBT-BF3	●	Growth
<b>CFU</b>	4 Billion / 1 Capsule	
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides)	
<b>DOSAGE FORM</b>	Vegetable Capsule	
<b>DIRECTION</b>	Take 1 capsule directly with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Infant fecal microbiota No adverse effects <sup>①</sup>	CBT-BT1, CBT-BR3, CBT-BG7, CBT-BF3
<i>in-vitro</i>	HMOs utilization <sup>②</sup> Vitamin B biosynthesis <sup>③</sup>	CBT-BT1, CBT-BR3, CBT-BG7, CBT-BF3
Genomic Research	Full genome sequencing <sup>④</sup>	CBT-BT1, CBT-BR3, CBT-BG7, CBT-BF3
Patent	Promotion of growth <sup>⑤</sup>	CBT-BT1, CBT-BR3, CBT-BG7, CBT-BF3

## KEY FEATURES

- To support gut health and maintain a beneficial vaginal flora for women
- Vaginal microbiota ecology, especially the high relative abundance of *Lactobacillus spp.*, is considered crucial for vaginal health in preventing the invasion of pathogens
- Clinically proven to improve vaginal health in women<sup>①</sup> aged 19-55 years
- CBT-LR6 have a high inhibitory activity against vaginal pathogens<sup>②</sup>, enhanced adherence to host cells, and high lactic acid production
- Experiments with CBT-LR6 revealed changes in both the fecal and vaginal microbiota<sup>③</sup>
- Easy to swallow vegetable capsule for women

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LR6 Feminine		
CBT-LA1	●	Obesity
CBT-LR5	●	Obesity
CBT-LU4		
<b>CFU</b>	5 Billion / 1 Capsule	
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides)	
<b>DOSAGE FORM</b>	Vegetable Capsule	
<b>DIRECTION</b>	Take 1 capsule directly with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Vaginal dysbiosis <sup>①</sup>	CBT-LA1, CBT-LR5, CBT-LU4
<i>in-vitro</i> , <i>in-vivo</i>	Characteristics of CBT-LR6 against vaginal pathogens <sup>②</sup>	CBT-LR6 Feminine
Patent	Prevention or treatment of obesity <sup>③</sup>	CBT-LA1, CBT-LR5



# FAMILY GUT HEALTH

LAB2PRO® BIO GUARD

ALL AGES

## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for all ages
- Clinically proven to reduce **obesity-related markers** such as waist circumference, total fat area, visceral fat, and ratio of visceral to subcutaneous fat area
- Proven to **inhibit the production of innate pro-inflammatory cytokines** during colitic progression
- CBT-LP3 as a potent **immunomodulator in IBD treatment**
- Antibacterial effect** against *E.coli* and *S. typhimurium*
- Patented strain for **preventing or treating obesity**
- Patented strain for **promotion of growth**
- Patented heat-killed bacteria **Prolac-T™** removes **lipopolysaccharides (LPS)** from the intestine, a common trigger of intestinal inflammation.

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	Obesity
CBT-LR5	●	Obesity
CBT-LP3	●	Obesity
CBT-SL6	●	
CBT-BF3	●	Growth
CBT-BR3	●	Growth
CBT-ST3	●	
Prolac-T™		Antibacterial Effect

<b>CFU</b>	5 Billion / 1 Stick
<b>OTHER INGREDIENT</b>	FOS, GOS, Vitamin D, Zinc
<b>DOSAGE FORM</b>	Stick Powder
<b>DIRECTION</b>	Take 1 stick with water

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Obesity ①	CBT-BR3, CBT-LP3
<i>in-vitro</i> & <i>in-vivo</i>	IBD ②	ALL
<i>in-vitro</i> & <i>in-vivo</i>	IBD, Anti-colitic effect ③	CBT-LP3
<i>in-vitro</i>	Antibacterial Activity ④	CBT-LA1, CBT-BF3, CBT-ST3
Patent	Prevention or treatment of obesity ⑤	CBT-LA1, CBT-LR5, CBT-LP3, CBT-BR3
Patent	Promotion of growth ⑥	CBT-BF3, CBT-BR3
<i>in-vitro</i> & <i>in-vivo</i>	Binding and removal of LPS ⑦	PROLAC-T™
Patent	Manufacturing methods of antibacterial compounds ⑧	PROLAC-T™



# FAMILY IMMUNE HEALTH

LAB2PRO® QUERCETIN

+13 YEARS

## KEY FEATURES

- To support gut health and maintain a beneficial gut flora for all ages
- “Tartary buckwheat” is a herbaceous plant known for its high levels of antioxidants, particularly “rutin”. These flavonoid compounds help reduce oxidative stress and inflammation, and they support cardiovascular health
- Through whole genome sequencing, **α-rhamnosidase and β-glucosidase are identified in the genome of CBT strains**, and these enzymes are associated with the bioconversion of rutin to quercetin
- Proven strains to **increase the content of quercetin** and **reduce the time of bioconversion of rutin to quercetin** which is a bioactive compound related to anti-inflammatory, antioxidants, anti-obesity, and anti-diabetes
- The multi-strain probiotics showed **increased bioconversion efficiency**, **effects of anti-oxidant and anti-inflammatory** compared to the single strain

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LP3	●	Obesity
CBT-SL6	●	
CBT-ST3	●	

<b>CFU</b>	3 Billion / 1 Stick
<b>OTHER INGREDIENT</b>	Tartary Buckwheat, Quercetin, Bromelain, Rutin
<b>DOSAGE FORM</b>	Stick Powder
<b>DIRECTION</b>	Take 1 stick with water

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<i>in-vitro</i>	Bioconversion of rutin ①	ALL
<i>in-vitro</i>	Bioconversion of rutin ②	ALL
Patent	Prevention or treatment of obesity ③	CBT-LP3



# GUT HEALTH

LAB2PRO® PREMIUM CARE

IBS, IBD, CONSTIPATION

## KEY FEATURES

- High-dose CFU formulation with multivitamins for complete bowel comfort
- Clinically proven to have an effect on the **global relief of IBS symptoms**
- Clinically proven to **attenuate diarrhea-related symptoms in IBS patients**
- Clinically proven to have a **significant improvement in constipation symptoms**
- Effective in **IBD healing by regulating interleukin-6**
- Antibacterial effect** against *E.coli* and *S. typhimurium*
- Patented composition for **preventing or treating IBS**
- Easy to swallow vegetable capsule for adult

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	IBS
CBT-LR5	●	IBS
CBT-BL3	●	IBS
CBT-BG7	●	IBS
CBT-BF3	●	IBS
CBT-ST3	●	IBS

<b>CFU</b>	10 Billion / 2 Sticks
<b>OTHER INGREDIENT</b>	FOS, GOS, Vitamin A, C, E, B1, B2, B6
<b>DOSAGE FORM</b>	Stick Powder
<b>DIRECTION</b>	Take 2 sticks with water

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Irritable bowel syndrome (IBS) ①	ALL
Clinical Trial	Irritable bowel syndrome (IBS) ②	ALL
Clinical Trial	Constipation ③	ALL
<i>in-vivo</i>	Inflammatory bowel disease (IBD) ④	ALL
<i>in-vitro</i>	Antibacterial effect ⑤	CBT-LA1, CBT-BF3, CBT-ST3
Patent	Irritable bowel syndrome (IBS) ⑥	ALL
Patent	Prevention or treatment of obesity ⑦	CBT-LA1, CBT-LR5, CBT-BL3



# GUT HEALTH

LAB2PRO® CALM GUT

IBS

## KEY FEATURES

- High-dose CFU formulation with Prolac-T™ for diarrhea-dominant IBS
- Clinically proven to significantly **improve overall discomfort of IBS-related symptoms**, and it had a **better effect on the ratio of normal stools** to hard or watery stools
- Clinically proven to **improve adequate relief of overall IBS symptoms** in Korean herbal medicine and a probiotic mixture group
- Patented heat-killed bacteria **Prolac-T™** removes **lipopolysaccharides (LPS)** from the intestine, a common trigger of intestinal inflammation.

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	
CBT-LP3	●	
CBT-LR5	●	
CBT-BR3	●	
CBT-BL3	●	
CBT-BG7	●	
CBT-ST3	●	
Prolac-T™		Antibacterial Effect

<b>CFU</b>	10 Billion / 1 Capsule
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides)
<b>DOSAGE FORM</b>	Vegetable Capsule
<b>DIRECTION</b>	Take 1 capsule directly with water

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Irritable bowel syndrome (IBS) ①	ALL
Clinical Trial	Irritable bowel syndrome (IBS) ②	ALL
<i>in-vitro</i> & <i>in-vivo</i>	Binding and removal of LPS ③	PROLAC-T™
Patent	Manufacturing methods of antibacterial compounds ④	PROLAC-T™

# GUT HEALTH

LAB2PRO® TRAVEL

DIARRHEA



## KEY FEATURES

- Special probiotics formulation with our unique patented postbiotics, ProLac-T™, maintains a healthy gut microflora during travel
- Live and heat-killed *Lactobacillus acidophilus* CBT-LA1 facilitates the excretion of *Salmonella* ①
- Inhibition of the growth of pathogenic bacteria ②, *Escherichia coli* (*E. coli*) and *Salmonella typhimurium* (*S. typhimurium*), which cause food poisoning and foodborne illness
- Treatment of immune cells with CBT-LA1, CBT-ST3, CBT-BF3 strains resulted in immune cells that were larger and rougher (activated) ② compared to those exposed only to the medium or LPS
- Treatment of immune cells with CBT-LA1, CBT-ST3, CBT-BF3 strains increases production of nitric oxide (NO) and TNF-α, which are key mediators of the immune response indicating CBT probiotics may reinforce immune function ②
- Patented heat-killed bacteria ProLac-T™ removes lipopolysaccharides (LPS) ③ from the intestine, a common trigger of intestinal inflammation.

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	
CBT-LP3	●	
CBT-BL3	●	
CBT-BF3	●	
CBT-ST3	●	
ProLac-T™		Antibacterial Effect
CFU	2.3 Billion / 1 Capsule	
OTHER INGREDIENT	FOS (Fructooligosaccharides)	
DOSAGE FORM	Vegetable Capsule or Tablet	
DIRECTION	Take 1 capsule directly with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<i>in-vitro</i> & <i>in-vivo</i>	Prevention of Salmonella ①	CBT-LA1
<i>in-vitro</i>	Antibacterial effect against foodborne bacteria ②	CBT-LA1, CBT-ST3, CBT-BF3
<i>in-vitro</i> & <i>in-vivo</i>	Binding and removal of LPS ③	PROLAC-T™
Patent	Manufacturing methods of antibacterial compounds ④	PROLAC-T™

# SKIN HEALTH

LAB2PRO® DERMA PLUS

ATOPIC DERMATITIS



## KEY FEATURES

- Special probiotics formulation to support skin health of your child
- Pediatric atopic dermatitis (AD) is a common, troublesome condition with limited treatment options, which has been associated with dysbiosis in the intestinal microflora
- Clinically proven to show more than 80% of children experienced improvement in AD symptoms ①, as measured by Severity Scoring of Atopic Dermatitis (SCORAD) index and significant reduction in the percentage of children with moderate-severe disease ②, declining from 92.4% at baseline to 28.1%
- Proven to significantly decrease the scratch score ③, an indicator of AD
- AD-like skin lesions treated with probiotics were milder ④ than those in the positive controlled group
- P14 protein of CBT-LC5, downregulating cytokine levels ⑤, as well as the AD index and scratching score

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LC5	●	Atopic Dermatitis
CBT-LP3	●	Atopic Dermatitis
CBT-LR5	●	Atopic Dermatitis
CBT-BL3	●	Atopic Dermatitis
CFU	10 Billion / 1 Stick	
OTHER INGREDIENT	FOS (Fructooligosaccharides), Biotin	
DOSAGE FORM	Stick Powder	
DIRECTION	Take 1 stick with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Alleviation of atopic dermatitis ①	ALL
<i>in-vivo</i>	Alleviation of atopic dermatitis ②	ALL
<i>in-vivo</i>	Alleviation of atopic dermatitis ③	ALL
<i>in-vitro</i> & <i>in-vivo</i>	Alleviation of atopic dermatitis ④	CBT-LC5
Patent	Preventing or treating atopic dermatitis ⑤	ALL

# WOMEN HEALTH

LAB2PRO® MENO-PRO

ANTI-MENOPAUSE



## KEY FEATURES

- β-glucosidase activity, the enzymatic action of CBT-LGA1 enhances the bioavailability of isoflavones ① from soy-based products
- The combination of soybean germ extract and CBT-LGA1 significantly improved body weight and uterine and bone health ②
- Moreover, it demonstrated promising effects on lipid profile, liver function, and vascular markers and positively impacted serotonin and norepinephrine levels, indicating potential mood-enhancing effects ③
- Clinically proven to improve vaginal health in women ④ aged 19-55 years
- CBT-LR6 have a high inhibitory activity against pathogens ⑤, enhanced adherence to host cells, and high lactic acid production
- Experiments with CBT-LR6 revealed changes in both the fecal and vaginal microbiota ⑥

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	Obesity
CBT-LR5	●	Obesity
CBT-LU4		
CBT-LR6		
Feminine CBT-LGA1		
CFU	1 Billion / 1 Capsule	
OTHER INGREDIENT	FOS (Fructooligosaccharides), S30 (Soybean Germ Extract)	
DOSAGE FORM	Vegetable Capsule	
DIRECTION	Take 1 capsule directly with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<i>in-vitro</i> & <i>in-vivo</i>	Anti-menopause effects ①	CBT-LGA1
Clinical Trial	Vaginal dysbiosis ②	CBT-LA1, CBT-LR5, CBT-LU4
<i>in-vitro</i> , <i>in-vivo</i>	Characteristics of CBT-LR6 against vaginal pathogens ③	CBT-LR6
Patent	Prevention or treatment of obesity ④	CBT-LA1, CBT-LR5

# LIVER HEALTH

LAB2PRO® FRESH MORNING

ANTI-HANGOVER



## KEY FEATURES

- Special probiotics formulation to help you feel better after drinking
- The ADH(alcohol dehydrogenase) and ALDH (aldehyde dehydrogenase) activities associated with *Lactobacillus* and *Bifidobacterium* have been reported (Nosova et al, 2000)
- Clinically proven to significantly downregulate blood levels of alcohol and acetaldehyde ① with ALDH2\*2/\*1 genotype subjects
- Proven to quickly lower blood alcohol and acetaldehyde concentrations ② in an alcohol and acetaldehyde dehydrogenase-dependent manner
- Proven to significantly reduce the serum ALT ③ (alanine aminotransferase) activity, which is biomarker of liver damage
- Formulated with milk thistle(silymarin), to promote healthy liver function

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LGA1		Alcohol Metabolism
CBT-LC5	●	Alcohol Metabolism
CBT-BL3	●	Alcohol Metabolism
CBT-BR3	●	Alcohol Metabolism
CFU	1 Billion / 1 Capsule	
OTHER INGREDIENT	FOS, Vitamin C, Milk Thistle, Protease, Amylase	
DOSAGE FORM	Vegetable Capsule	
DIRECTION	Take 1 capsule directly with water	

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
Clinical Trial	Alcohol and Acetaldehyde Metabolism ①	ALL
<i>in-vitro</i> & <i>in-vivo</i>	Alcohol and Acetaldehyde Metabolism ②	ALL
Patent	Composition containing of probiotics for using alcohol or acetaldehyde dehydrogenase activity ③	CBT-LGA1, CBT-LC5, CBT-BL3, CBT-BR3, CBT-SL4(PP1)

# MUSCLE HEALTH

LAB2PRO® PROTEIN PLUS

PROTEIN ABSORPTION

## KEY FEATURES

- A special probiotics formulation designed to **enhance protein absorption in the gut** and promote gut comfort for regular protein consumers
- Probiotics are known to improve dietary protein digestion and absorption via gut-bacterial enzymatic activity, leading to enhanced amino acid availability for protein synthesis (Marco et al, 2021)
- 20 Aminopeptidase activity of CBT strains were measured
- The concentration of 19 amino acids was measured after incubating 4 protein supplements (WPC, WPI, ISP, MPI) with or without CBT probiotics
- A combination of 4 protein supplement and CBT probiotics **increased amino acid concentrations in serum** compared to a group received only protein supplement.
- Furthermore, this combination **recovered expression of mRNAs related to growth of muscle cell**
- Clinically proven to have an effect on the **global relief of IBS symptoms**
- Clinically proven to have a **significant improvement in constipation symptoms**
- Patented strain for **preventing or treating obesity**

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	Obesity
CBT-LP3	●	Obesity
CBT-LR5	●	Obesity
CBT-BF3	●	
CBT-BG7	●	
CBT-BL3	●	Obesity
CBT-ST3	●	

<b>CFU</b>	10 Billion /1 Stick
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides), BCAA
<b>DOSAGE FORM</b>	Vegetable Capsule
<b>DIRECTION</b>	Take 1 capsule directly with water

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<b>in-vitro &amp; in-vivo</b>	Protein Absorption	ALL
<b>Clinical Trial</b>	Irritable bowel syndrome (IBS)	CBT-LA1, CBT-LR5, CBT-BF3, CBT-BG7, CBT-BL3, CBT-ST3
<b>Clinical Trial</b>	Constipation	CBT-LA1, CBT-LR5, CBT-BF3, CBT-BG7, CBT-BL3, CBT-ST3
<b>Patent</b>	Prevention or treatment of obesity	CBT-LA1, CBT-LP3, CBT-LR5, CBT-BL3
<b>Patent</b>	Irritable bowel syndrome (IBS)	CBT-LA1, CBT-LR5, CBT-BF3, CBT-BG7, CBT-BL3, CBT-ST3

# ORAL HEALTH

LAB2PRO® DENTAL

CAVITY, PERIODONTITIS

## KEY FEATURES

- Special probiotics formulation for a healthy mouth environment
- *S. mutans* are highly associated with human dental caries. So, inhibition of the growth of *S. mutans* is thought to be one of the most important factors in preventing dental caries. However, continuous and long-term use of antibiotics for dental treatment involves the risks of disturbing the intestinal microflora and of other adverse effects on human health. Therefore, an inhibitor of *S. mutans* growth without adverse effects is desired (Lee et al., 2021)
- The cell culture filtrate of CBT-LA1 and CBT-LP3, which contains antimicrobial substances, **inhibits the growth of harmful oral bacteria, *S. mutans***
- Patented composition for **antibacterial activity on *S. mutans***
- Formulated with brazilian green propolis powder, a natural biomaterial for oral healthcare

## UNIQUE FORMULATION

Name		Patent
CBT-LA1	Supernatants (Strain culture filtrate)	Antibacterial Activity
CBT-LP3	Supernatants (Strain culture filtrate)	Antibacterial Activity

<b>CFU</b>	30 AU / 1 Tablet
<b>OTHER INGREDIENT</b>	Xylitol, Applemint flavor, Peppermint flavor, Propolis powder
<b>DOSAGE FORM</b>	Chewable Tablet
<b>DIRECTION</b>	Take 1 tablet and let it slowly dissolve

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<b>Patent</b>	Antibacterial activity on <i>Streptococcus mutans</i>	ALL

# MENTAL HEALTH

LAB2PRO® GOOD MOOD

DEPRESSION

## KEY FEATURES

- Special probiotics formulation for support stress relief
- Gastrointestinal microbiome are known to produce and deliver neuroactive substances acting on the gut-brain axis. Although the pathways are not clearly understood, changes in the gastrointestinal microbiome play an important role in the function of the central nervous system, and thereby affect mental disorders such as depression (Jiang, Haiyin, et al.)
- Genome sequencing confirmed that CBT-LP3 has the **genes encoding the GABA-related enzyme**, glutamate decarboxylase and the **serotonin-related enzyme**, serotonin N-acetyl transferase
- HPLC analysis **confirmed the expression of GABA**, in CBT-LP3 compared to control group
- Proven to **alleviate depressive-like behaviors**, and decreased corticosterone level
- Specially formulated with affron®, a premium saffron ingredient, clinically proven to maintain a positive mood

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LP3	●	
CBT-LR5	●	
CBT-BL3	●	
CBT-BR3	●	
CBT-SL4		

<b>CFU</b>	7.5 Billion / 1 Capsule
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides), affron® (Saffron extract)
<b>DOSAGE FORM</b>	Vegetable Capsule
<b>DIRECTION</b>	Take 1 capsule directly with water

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<b>Genomic Analysis</b>	Gene analysis of GABA and serotonin related enzymes	CBT-LP3
<b>in-vitro</b>	HPLC analysis of GABA	CBT-LP3
<b>in-vivo</b>	Depressive behaviors and decreased corticosterone level	ALL

# PET HEALTH

LAB2PRO® SLIM DOG

WEIGHT MANAGEMENT

## KEY FEATURES

- Special probiotics formulation to support your dog's digestive health and weight management
- Patented strain for **preventing or treating obesity**
- This patented composition **inhibit fat cell differentiation, reduce body fat mass, decrease visceral fat mass, reduce glucose and total cholesterol levels**, and lead to decreased plasma and hepatic triglyceride levels
- Specially formulated with glucosamine for joint health
- Micro sized tablet is easy to treat and chew for small pups
- A veterinary clinical trial involving dogs is currently underway and is expected to conclude in 2024

## UNIQUE FORMULATION

Name	GRAS	Patent
CBT-LA1	●	Obesity
CBT-LP3	●	Obesity
CBT-LR5	●	Obesity
CBT-BR3	●	Obesity
CBT-BL3	●	Obesity
CBT-SL4		Obesity

<b>CFU</b>	1 Billion / 1 Sachet
<b>OTHER INGREDIENT</b>	FOS (Fructooligosaccharides), Glucosamine
<b>DOSAGE FORM</b>	Micro Tablet
<b>DIRECTION</b>	Give 1 sachet directly or mix with dog food

## SCIENTIFIC EVIDENCE

Study Design	Subject	Strain
<b>Patent</b>	Prevention or treatment of obesity	ALL
<b>Veterinary clinical trial (dog)</b>	Obesity – to be published in 2024	CBT-LP3, CBT-BR3

# ENDNOTE

## p.04

- 1 Bazanella, Monika, et al. "Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome." *The American journal of clinical nutrition* 106.5 (2017): 1274-1286.
- 2 Jung, Hye Su, et al. "Investigation on human milk oligosaccharide utilization and vitamin B biosynthesis by Bifidobacterium strains isolated from infant feces." *The Microbiological Society of Korea* 56.3 (2020): 297-306.
- 3 Kwak, Min-Jung, et al. "Evolutionary architecture of the infant-adapted group of Bifidobacterium species associated with the probiotic function." *Systematic and applied microbiology* 39.7 (2016): 429-439.
- 4 KR10-1589465, KR10-1589464, KR10-1589466, KR10-1589467
- 5 Lee, Do Kyung, et al. "Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients." *Clinics and research in hepatology and gastroenterology* 39.2 (2015): 237-244.
- 6 Park, Jae Eun, et al. "Antiviral Properties of Probiotic Mixtures against Rotavirus in the Rat." *Korean Journal of Microbiology* 50.4 (2014): 296-301.
- 7 Hong, Un-Pyo, et al. "Protection of Infection and Eradication Activity of Culture Product by *Pediococcus pentosaceus* CBT SL4 Showing Antimicrobial Activity against *Helicobacter pylori*." *Korean Journal of Food Science and Technology* 36.5 (2004): 779-783.
- 8 Kim, Da Hye, et al. "Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice." *International Journal of Medical Microbiology* 310.2 (2020): 151391.
- 9 Kim, Da Hye, et al. "Lactobacillus acidophilus suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress." *Journal of Gastroenterology and Hepatology* 34.1 (2019): 178-185.
- 10 Jung, Hye Su, et al. "Investigation on human milk oligosaccharide utilization and vitamin B

biosynthesis by Bifidobacterium strains isolated from infant feces." *The Microbiological Society of Korea* 56.3 (2020): 297-306.

11 KR10-1589466

## p.05

- 1 Putra, I. Gusti Ngurah Sanjaya, Sudaryat Suraatmaja, and I. Ketut Nomor Aryasa. "Effect of probiotics supplementation on acute diarrhea in infants: a randomized double blind clinical trial." *Paediatrica Indonesiana* 47.4 (2007): 172-8.
- 2 Arifin, Zainul, Aswitha D. Boediarso, and Taralan Tambunan. "Probiotic treatment in children with lactose intolerance "An open labeled the one group pre-test post-test experimental study." *Paediatrica Indonesiana* 46.3 (2006): 139-43.
- 3 Jung, Hye Su, et al. "Investigation on human milk oligosaccharide utilization and vitamin B biosynthesis by Bifidobacterium strains isolated from infant feces." *The Microbiological Society of Korea* 56.3 (2020): 297-306.
- 4 KR10-1589466
- 5 Lee, Do Kyung, et al. "Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients." *Clinics and research in hepatology and gastroenterology* 39.2 (2015): 237-244.
- 6 Hong, Un-Pyo, et al. "Protection of Infection and Eradication Activity of Culture Product by *Pediococcus pentosaceus* CBT SL4 Showing Antimicrobial Activity against *Helicobacter pylori*." *Korean Journal of Food Science and Technology* 36.5 (2004): 779-783.
- 7 Kim, Da Hye, et al. "Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice." *International Journal of Medical Microbiology* 310.2 (2020): 151391.
- 8 Kim, Da Hye, et al. "Lactobacillus acidophilus suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress." *Journal of Gastroenterology and Hepatology* 34.1 (2019): 178-185.
- 9 Jung, Hye Su, et al. "Investigation on human

milk oligosaccharide utilization and vitamin B biosynthesis by Bifidobacterium strains isolated from infant feces." *The Microbiological Society of Korea* 56.3 (2020): 297-306.

10 KR10-1589466

11 KR10-1611837, KR10-1611834, KR10-1611833, KR10-1611832, KR10-1611829

## p.06

- 1 Yoon, Jun Sik, et al. "Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial." *Journal of gastroenterology and hepatology* 29.1 (2014): 52-59.
- 2 Yoon, Hyuk, et al. "Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial." *Journal of clinical biochemistry and nutrition* 57.2 (2015): 129-134.
- 3 Yeun, Youngran, and Jaejin Lee. "Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study." *Archives of pharmacol research* 38 (2015): 1345-1350.
- 4 Yoon, Hyunho, et al. "A probiotic preparation duolac-gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6." *Toxicological Research* 30.1 (2014): 27-32.
- 5 Park, So-Hee, et al. "Antibacterial activity and macrophage activation of lactic acid bacteria." *Environmental Analysis Health and Toxicology* 22.4 (2007): 287-297.
- 6 KR10-1453982
- 7 KR10-1611833, KR10-1611837, KR10-1611832
- 8 Song, S.-C., et al. "Beneficial effects of a probiotic blend on gastrointestinal side effects induced by leflunomide and amlodipine in a rat model." *Beneficial Microbes* 8.5 (2017): 801-808.
- 9 Byun, S. J., et al. "In vivo effects of s-pantoprazole, polaprenzinc, and probiotic blend on chronic small intestinal injury induced by indomethacin." *Beneficial Microbes* 7.5 (2016): 731-737.

10 So, Jae-Seon, et al. "Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions." *Molecular immunology* 45.9 (2008): 2690-2699.

- 11 Shin, Joo-Hyun, Joong-Su Lee, and Jae-Gu Seo. "Assessment of cell adhesion, cell surface hydrophobicity, autoaggregation, and lipopolysaccharide-binding properties of live and heat-killed *Lactobacillus acidophilus* CBT LA1." *미생물학회지* 51.3 (2015): 241-248.
- 12 KR10-1453982
- 13 KR10-1369219

## p.07

- 1 Bazanella, Monika, et al. "Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome." *The American journal of clinical nutrition* 106.5 (2017): 1274-1286.
- 2 Jung, Hye Su, et al. "Investigation on human milk oligosaccharide utilization and vitamin B biosynthesis by Bifidobacterium strains isolated from infant feces." *The Microbiological Society of Korea* 56.3 (2020): 297-306.
- 3 Kwak, Min-Jung, et al. "Evolutionary architecture of the infant-adapted group of Bifidobacterium species associated with the probiotic function." *Systematic and applied microbiology* 39.7 (2016): 429-439.
- 4 Yoon, Hyunho, et al. "A probiotic preparation duolac-gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6." *Toxicological Research* 30.1 (2014): 27-32.
- 5 Park, So-Hee, et al. "Antibacterial activity and macrophage activation of lactic acid bacteria." *Environmental Analysis Health and Toxicology* 22.4 (2007): 287-297.
- 6 Ansari, AbuZar, et al. "Lactobacillus Probiotics Improve Vaginal Dysbiosis in Asymptomatic Women." *Nutrients* 15.8 (2023): 1862.
- 7 Chung, Yusook, et al. "Characterization of the probiotic properties of *Lacticaseibacillus rhamnosus* LR6 isolated from the vaginas of healthy Korean women against vaginal pathogens." *Frontiers in Microbiology* 14 (2023): 1308293.
- 8 KR10-1611833, KR10-1611837

## p.08

- 1 Song, Eun-Ji, et al. "Effect of probiotics on

obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial." *EPMA Journal* 11 (2020): 31-51.

- 2 Kim, M. S., et al. "A probiotic combination attenuates experimental colitis through inhibition of innate cytokine production." *Beneficial microbes* 8.2 (2017): 231-241.
- 3 Kim, Da Hye, et al. "Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice." *International Journal of Medical Microbiology* 310.2 (2020): 151391.
- 4 Park, So-Hee, et al. "Antibacterial activity and macrophage activation of lactic acid bacteria." *Environmental Analysis Health and Toxicology* 22.4 (2007): 287-297.
- 5 KR10-1611833, KR10-1611837, KR10-1611834, KR10-1611830
- 6 KR10-1589467, KR10-1589465
- 7 Shin, Joo-Hyun, Joong-Su Lee, and Jae-Gu Seo. "Assessment of cell adhesion, cell surface hydrophobicity, autoaggregation, and lipopolysaccharide-binding properties of live and heat-killed *Lactobacillus acidophilus* CBT LA1." *미생물학회지* 51.3 (2015): 241-248.
- 8 Kwon, Chang, et al. "Bioconversion of Rutin in Tartary Buckwheat by the Korean Indigenous Probiotics." (2023): 83-92.
- 9 Kim, Song-in, et al. "Comparison of Bioconversion Ability and Biological Activities of Single and Multi-Strain Probiotics for an Active Molecule in Roasted Tartary Buckwheat." (2023): 465-473.
- 10 KR10-1611834

## p.09

- 1 Yoon, Jun Sik, et al. "Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial." *Journal of gastroenterology and hepatology* 29.1 (2014): 52-59.
- 2 Yoon, Hyuk, et al. "Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind,

placebo-controlled trial." *Journal of clinical biochemistry and nutrition* 57.2 (2015): 129-134.

- 3 Yeun, Youngran, and Jaejin Lee. "Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study." *Archives of pharmacol research* 38 (2015): 1345-1350.
- 4 Yoon, Hyunho, et al. "A probiotic preparation duolac-gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6." *Toxicological Research* 30.1 (2014): 27-32.
- 5 Park, So-Hee, et al. "Antibacterial activity and macrophage activation of lactic acid bacteria." *Environmental Analysis Health and Toxicology* 22.4 (2007): 287-297.
- 6 KR10-10-1453982
- 7 KR10-1611833, KR10-1611837, KR10-1611832
- 8 Han, Kyungsun, et al. "Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial." *Journal of gastroenterology* 52 (2017): 432-443.
- 9 Ko, Seok-Jae, et al. "Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial." *Evidence-based Complementary and Alternative Medicine* 2013 (2013).
- 10 Shin, Joo-Hyun, Joong-Su Lee, and Jae-Gu Seo. "Assessment of cell adhesion, cell surface hydrophobicity, autoaggregation, and lipopolysaccharide-binding properties of live and heat-killed *Lactobacillus acidophilus* CBT LA1." *Korean Journal of Microbiology* 51.3 (2015): 241-248.
- 11 KR 10-1369219

## p.10

- 1 Kim, Min-Soo, et al. "A study on the prevention of salmonella infection by using the aggregation characteristics of lactic Acid bacteria." *Toxicological research* 29.2 (2013): 129-135.

- 2 Park, So-Hee, et al. "Antibacterial activity and macrophage activation of lactic acid bacteria." *Environmental Analysis Health and Toxicology* 22.4 (2007): 287-297.
- 3 Shin, Joo-Hyun, Joong-Su Lee, and Jae-Gu Seo. "Assessment of cell adhesion, cell surface hydrophobicity, autoaggregation, and lipopolysaccharide-binding properties of live and heat-killed *Lactobacillus acidophilus* CBT LA1." *미생물학회지* 51.3 (2015): 241-248.
- 4 KR10-1369219
- 5 Ibáñez, M. Dolores, et al. "Effect of synbiotic supplementation on children with atopic dermatitis: an observational prospective study." *European Journal of Pediatrics* 177 (2018): 1851-1858.
- 6 Seo, Jae-Gu, Myung-Jun Chung, and Hyun-Gi Lee. "Alleviation of atopic dermatitis through probiotic and mixed-probiotic treatments in an atopic dermatitis model." *Korean J Food Sci Animal Resour* 31 (2011): 420-7.
- 7 Kim, Min-Soo, et al. "A probiotic preparation alleviates atopic dermatitis-like skin lesions in murine models." *Toxicological Research* 32 (2016): 149-158.
- 8 Kim, Min-Soo, et al. "Improvement of atopic dermatitis-like skin lesions by IL-4 inhibition of P14 protein isolated from *Lactobacillus casei* in NC/Nga mice." *Applied microbiology and biotechnology* 99 (2015): 7089-7099.
- 9 KR10-1724601

## p.11

- 1 Lee, Sun-Hee, et al. "Anti-Menopausal Effect of Soybean Germ Extract and *Lactobacillus gasseri* in the Ovariectomized Rat Model." *Nutrients* 15.20 (2023): 4485.
- 2 Ansari, AbuZar, et al. "Lactobacillus Probiotics Improve Vaginal Dysbiosis in Asymptomatic Women." *Nutrients* 15.8 (2023): 1862.
- 3 Chung, Yusook, et al. "Characterization of the probiotic properties of *Lacticaseibacillus rhamnosus* LR6 isolated from the vaginas of healthy Korean women against vaginal pathogens." *Frontiers in Microbiology* 14 (2023):

1308293.

4 KR10-1611833, KR10-1611837

- 5 Jung, Su-Jin, et al. "Regulation of alcohol and acetaldehyde metabolism by a mixture of *Lactobacillus* and *bifidobacterium* species in human." *Nutrients* 13.6 (2021): 1875.
- 6 Lim, Tae-Joong, et al. "Effects of multi-species probiotic supplementation on alcohol metabolism in rats." *Journal of Microbiology* 59 (2021): 417-425.

7 KR10-1853603

## p.12

- 1 Chung, Yusook, et al. "Effects of Proteolytic Activity of Multi-Species Probiotics on Dietary Protein Absorption and Muscle Physiology." (2023): 616-627.
- 2 Yoon, Jun Sik, et al. "Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial." *Journal of gastroenterology and hepatology* 29.1 (2014): 52-59.
- 3 Yeun, Youngran, and Jaejin Lee. "Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study." *Archives of pharmacol research* 38 (2015): 1345-1350.
- 4 KR10-1611833, KR10-1611834, KR10-1611837, KR10-1611832
- 5 KR10-1453982
- 6 KR10-2488050

## p.13

- 1 Cell Biotech R&D Center, 2022
- 2 Cell Biotech R&D Center, 2022
- 3 Liu, Quan Feng, et al. "Effect of probiotic administration on gut microbiota and depressive behaviors in mice." *DARU Journal of Pharmaceutical Sciences* 28 (2020): 181-189.
- 4 KR10-1611833, KR10-1611834, KR10-1611837, KR10-1611830, KR10-1611832, KR10-1611829

**CELL BIOTECH**

50, Aegibong-ro, 409 Beon-gil, Wolgot-myeon, Gimpo-si, Gyeonggido, 10003, Korea

**TEL** (+82)-31-987-6205 **FAX** (+82)-31-987-6209 **WEB** [www.cellbiotech.com](http://www.cellbiotech.com)

**CELL BIOTECH International**

Bluecom Tower, Seocho-daero 274, Seocho-gu, Seoul, 06645, Korea

**TEL** (+82)-2-2668-6077 **FAX** (+82)-2-2668-6511

**CELL BIOTECH International A/S**

Strandvejen 125, DK-2900 Hellerup, Denmark

**TEL** (+45)3977-5040

This communication is only intended for business-to-business and health care professionals.

This communication is not intended for consumers of final consumer goods.

Nothing on this brochure is meant to be perceived as an approved claim.